Description
17α-Methyl-1-Testosterone (M1T, Methyl-1-Test) is a synthetic testosterone derivative with 17α-methyl group and an additional 1-dehydro modification. The substance appeared in the 2000s as a prohormone supplement in the US market and was quickly banned due to extreme hepatotoxicity.
Per study reports M1T binds with very high affinity to the androgen receptor - in animal studies an anabolic action factor of 12-19x testosterone was reported, with androgenic action factor 2-9x. The substance doesn’t aromatize to estradiol, so it’s “dry” in action profile.
The central property that made M1T famously notorious: extreme potency at tiny doses. 5-10mg/day equals in action 50-100mg/day Dianabol. Research reports from the recreational community speak of 4-6kg lean mass gain in 3-4 weeks.
Hepatotoxicity is correspondingly extreme. M1T belongs with Methasterone and Halotestin to the most toxic oral anabolics overall. Case reports of severe liver damage are documented in medical literature.
Pharmacokinetically orally bioavailable with about 8-10 hour half-life. Bioavailability high due to 17α-methyl group.
Known effects in studies and case reports: massive ALT/AST elevations often by the second week, cholestasis, lethargy and general malaise (“M1T lethargy” as phenomenon in practice), appetite loss, hypertension. Cycle duration is strictly limited to 2-3 weeks.
M1T is on the WADA banned list.
You can order Methyl-1-Testosterone as oral tablets in one bottle with 10mg per tablet.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Methyl-1-Testosterone is among the most toxic oral anabolics overall and therefore sits at the top end of the risk scale. The effects documented in the literature are severe and often appear early in the protocol.
Documented in studies and the user literature:
- Severe liver strain: as a 17α-methyl steroid, M1T is extremely hepatotoxic. Massive ALT/AST elevations often by the second week and cholestasis are documented in case reports.
- Lethargy and malaise: pronounced lethargy, general malaise and appetite loss are documented in the user literature.
- Cardiovascular: hypertension is described in studies.
- Suppression of natural production: a pronounced HPG suppression with delayed recovery is documented in the literature.
Baseline bloodwork before, during and after a research protocol is strongly advised. This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Endocrine Characterization of the Designer Steroid Methyl-1-Testosterone: Investigations on Tissue-Specific Anabolic-Androgenic Potency, Side Effects, and Metabolism - Endocrinology 2011, Parr et al: core characterization study in rats on AR binding, tissue-specific anabolic and androgenic potency, hepatotoxicity and urinary metabolism of M1T.
- Hepatotoxicity Associated With Dietary Supplements Containing Anabolic Steroids - Clinical Gastroenterology and Hepatology 2007, Kafrouni et al: case series of cholestatic liver injury after consumption of dietary supplements containing M1T and related designer steroids.
- Acute Kidney Injury Due to Interaction of Methyl-1-testosterone with Ciclosporin Metabolism in a Patient with Severe Atopic Dermatitis - Dermatology and Therapy 2013: case report on CYP-mediated interaction with ciclosporin and resulting acute kidney injury under M1T.
- Mission Compromised? Drug-Induced Liver Injury From Prohormone Supplements Containing Anabolic-Androgenic Steroids in Two Deployed U.S. Service Members - Military Medicine 2016, Magee et al: two military case reports of drug-induced liver injury including cholestatic jaundice after prohormone supplements containing M1T and related substances.
- Designer steroids - over-the-counter supplements and their androgenic component: review of an increasing problem - Andrology 2015, Rahnema et al: review article on designer steroids including M1T with focus on hepatotoxicity, cholestasis and endocrine side effects.
